Reference : The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal an...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/168405
The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.
English
Abizaid, Alexandre [> >]
Costa, J. Ribamar Jr [> >]
Banning, Adrian [> >]
Bartorelli, Antonio L. [> >]
Dzavik, Vladimir [> >]
Ellis, Stephen [> >]
Gao, Runlin [> >]
Holmes, David R. Jr [> >]
Jeong, Muyng Ho [> >]
Legrand, Victor mailto [Université de Liège - ULiège > Département des sciences cliniques > Cardiologie >]
Neumann, Franz-Josef [> >]
Nyakern, Maria [> >]
Orlick, Amy [> >]
Spaulding, Christian [> >]
Worthley, Stephen [> >]
Urban, Philip M. [> >]
2012
JACC. Cardiovascular Interventions
5
1
64-71
Yes (verified by ORBi)
International
1936-8798
1876-7605
United States
[en] Angioplasty, Balloon, Coronary ; Coronary Restenosis/mortality/prevention & control ; Databases, Factual ; Drug-Eluting Stents/adverse effects/statistics & numerical data ; Europe ; Female ; Health Status Indicators ; Humans ; Immunosuppressive Agents/therapeutic use ; Internationality ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Product Surveillance, Postmarketing ; Registries ; Sirolimus/therapeutic use ; Statistics as Topic
[en] OBJECTIVES: This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. BACKGROUND: There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. METHODS: The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. RESULTS: Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%, p < 0.001), renal insufficiency (5.8% vs. 2.3%, p = 0.003), and prior coronary artery bypass graft (20.5% vs. 11.8%, p < 0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). CONCLUSIONS: Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.
http://hdl.handle.net/2268/168405
10.1016/j.jcin.2011.09.016
Copyright (c) 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
the sirolimus.pdfPublisher postprint2.02 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.